This bill extends through October 12, 2036, the authority of the Department of the Interior to provide any assistance to the Arabia Mountain National Heritage Area in Georgia.
This bill requires the Department of Health and Human Services (HHS) to submit a report analyzing the impact on global COVID-19 vaccine access of a waiver of certain obligations held by nations who are members of the Agreement on Trade-Related Aspects of Intellectual Property Rights. (India and South Africa previously submitted a petition to suspend all intellectual property rights associated with COVID-19 innovations, such as vaccines.) Based on this report, the U.S. Trade Representative must oppose such elimination or waiver with respect to COVID-19 vaccines if HHS determines that the elimination or waiver will not materially increase global vaccine access or that it will have a negative impact on specified factors relating to access to, manufacture of, and investment in COVID-19 vaccines.
Emergency Resupply for IRON DOME Act of 2021 This bill requires the President to make all unexpended funding for assistance to Gaza available instead for grants to Israel for its Iron Dome short-range rocket defense system.
Hamas International Financing Prevention Act This bill imposes sanctions targeting Hamas, the Palestinian Islamic Jihad, and any affiliate or successor groups. The President shall periodically report to Congress a list of each foreign person or instrumentality that knowingly assists, provides significant support or services to, or is involved in a significant transaction with a senior member or supporter of any of the targeted groups. The President shall impose two or more sanctions on the named persons. Specifically, the person may be (1) denied credit and services from the Export-Import Bank, (2) barred from purchasing certain controlled defense articles, (3) denied exports of items on the U.S. Munitions List, (4) prevented from receiving exports of certain goods or technology controlled for national security reasons, (5) prohibited from receiving financing of more than $10 million from any U.S. financial institution, or (6) subject to property-blocking restrictions. The President shall periodically report to Congress a list of foreign governments that have repeatedly provided material support for the targeted groups' terrorist activities. The President shall bar these governments from receiving for one year (1) U.S. assistance, or (2) exports of controlled munitions. The Department of Treasury shall instruct U.S. leadership of international financial institutions to oppose the provision of assistance to an identified government for one year. The bill provides for certain exceptions and waivers, such as for transactions that would serve U.S. national interests. The President shall report to Congress and periodically provide briefings on other specified topics related to the targeted groups, such as where these groups secure financing and surveillance equipment.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021 This bill relaxes certain requirements for compounding drugs that are facing shortages. Drug compounding is the process of mixing or otherwise altering drugs to create a medication. Currently, the Food and Drug Administration (FDA) allows for drug compounding subject to certain requirements. Generally a licensed pharmacist or physician not registered with the FDA may only compound drugs in limited quantities for prescriptions for a specific individual patient. On the other hand, an FDA-registered outsourcing facility may compound drugs in bulk for use in medical facilities but is subject to additional requirements. This bill allows a compounder not registered with the FDA to compound drugs in limited quantities for urgent medical need not involving a specific patient if, among other things, (1) the prescriber certifies that they are unable to obtain, despite reasonable attempts, certain related drugs with the same active ingredient and route of administration; (2) the compounded drug meets certain labeling requirements, including an indication that the compounded drug is provided only for urgent administration to a patient; and (3) the compounder requests and maintains certain records about patients receiving the compounded drug. Furthermore, a restriction against an unregistered compounder regularly compounding (or compounding inordinate amounts of) what is essentially a copy of a commercially available drug shall not apply if the drug is on a shortage list maintained by the FDA or the American Society of Hospital Pharmacists.
Armed Forces Transgender Dependent Protection Act This bill expands the policy of the Office of Special Needs within the Department of Defense to address transgender dependents. Specifically, the bill codifies the definition of a medical or educational special need to include gender dysphoria. Under the bill, the policy of the office must prohibit the assignment of a military family with special needs to a permanent duty location where the law restricts medically necessary treatment for a medical or educational special need. A member who is serving at a location when such a law is established may elect to be reassigned.
Made in America Emergency Preparedness Act This bill establishes in the legislative branch the National Commission on United States Preparedness for National Emergencies and requires any medical, pharmaceutical, or emergency preparedness product deemed integral to a response to a national emergency to be manufactured and procured in the United States beginning on and after January 1, 2026. The commission must, among other things, examine and report on the COVID-19 pandemic in the United States in 2020 and the private sector response, investigate the origin of the COVID-19 virus and measures for mitigating the impacts of future physical and medical national disasters, determine what medical, pharmaceutical, and emergency preparedness products are deemed to be essential to emergency preparedness, and report on infrastructure or capability deficiencies in hospitals and medical centers. States must implement the commission's findings or lose access to federal emergency preparedness funds. The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property (e.g., personal protective equipment) placed in service after 2020 and before 2027.
State and Local General Sales Tax Protection Act This bill restricts the source of revenue for airport spending to local fuel excise taxes. Under current Federal Aviation Administration policy, state and local governments must also use general sales taxes collected on aviation fuel for airport spending.
Clean Water Standards for PFAS Act of 2021 This bill directs the Environmental Protection Agency (EPA) to develop requirements and incentives to limit the discharge of perfluoroalkyl and polyfluoroalkyl substances (PFAS) into certain waters of the United States. PFAS are man-made and may have adverse human health effects. A variety of products contain the compounds, such as nonstick cookware or weatherproof clothing. Within two years, the EPA must publish water quality criteria for each measurable perfluoroalkyl substance, polyfluoroalkyl substance, and class of PFAS. The water quality criteria must determine how much of these substances can be present in water before it is likely to harm human health. Within four years, the EPA must publish a final rule that establishes, for each priority industry category specified in the bill, effluent limitations guidelines and standards for the discharge of each measurable perfluoroalkyl substance, polyfluoroalkyl substance, and class of PFAS. Under the Clean Water Act, effluent limitations restrict the quantities, rates, and concentrations of chemical, physical, biological, and other constituents which are discharged from point sources (e.g., a discernible source such as a pipe) into navigable waters, the ocean, or other specified waters. In addition, the EPA must award grants to owners and operators of publicly owned treatment works for implementing the effluent limitations guidelines and standards.
National and Regional Greenways Act This bill requires the Department of Transportation (DOT) to establish a grant program for states, localities, and tribes to support community greenway paths for walking, bicycling, and other motor vehicle alternatives. DOT must designate eligible greenway paths that are considered regionally or nationally significant through a national greenway paths network; paths must cross multiple localities or states, reduce congestion, improve safety, benefit the environment, support communities, or meet other specified criteria. Eligible projects must support access to public parks, transportation, and other community needs.
Safe Roads Act of 2021 This bill directs the Department of Transportation (DOT) to implement motor vehicle safety standards that (1) require certain truck-tractors with electronic stability control systems to be equipped with an automatic emergency braking system, (2) establish performance requirements for such braking systems, and (3) require such systems to be used while the truck-tractors are in operation. DOT must also study and report on equipping commercial motor vehicles with automatic emergency braking to avoid or mitigate a collision with an obstacle in the path of the vehicle.
This bill requires the Environmental Protection Agency (EPA) to amend its regulations to revise the standards for the emission of ethylene oxide. Specifically, regulations must be revised based on results from the National Center for Environmental Assessment report titled Evaluation of the Inhalation Carcinogenicity of Ethylene Oxide . The bill also requires revisions to apply maximum achievable control technology requirements to chamber exhaust vents. Maximum achievable control technology standards are established for sources of hazardous air pollutants to limit or control emissions. Additionally, the revisions must apply to area sources and major sources of ethylene oxide. The EPA must carry out a residual risk assessment with respect to the revised standards. Finally, the EPA must notify the public of violations under the revised standards, and failure to do so will result in an investigation to assess the health risks and prevent a future failure of notification.
